350 related articles for article (PubMed ID: 29878355)
21. Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Pugalenthi A; Protic M; Gonen M; Kingham TP; Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ
J Surg Oncol; 2016 Feb; 113(2):188-93. PubMed ID: 26678349
[TBL] [Abstract][Full Text] [Related]
22. Major Postoperative Complications Limit Adjuvant Therapy Administration in Patients Undergoing Pancreatoduodenectomy for Distal Cholangiocarcinoma or Pancreatic Ductal Adenocarcinoma.
Macfie R; Berger Y; Liu H; Li T; Imtiaz S; Ang C; Sarpel U; Hiotis S; Labow D; Golas B; Cohen NA
Ann Surg Oncol; 2023 Aug; 30(8):5027-5034. PubMed ID: 37210446
[TBL] [Abstract][Full Text] [Related]
23. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis.
Mackay TM; Smits FJ; Roos D; Bonsing BA; Bosscha K; Busch OR; Creemers GJ; van Dam RM; van Eijck CHJ; Gerhards MF; de Groot JWB; Groot Koerkamp B; Haj Mohammad N; van der Harst E; de Hingh IHJT; Homs MYV; Kazemier G; Liem MSL; de Meijer VE; Molenaar IQ; Nieuwenhuijs VB; van Santvoort HC; van der Schelling GP; Stommel MWJ; Ten Tije AJ; de Vos-Geelen J; Wit F; Wilmink JW; van Laarhoven HWM; Besselink MG;
HPB (Oxford); 2020 Feb; 22(2):233-240. PubMed ID: 31439478
[TBL] [Abstract][Full Text] [Related]
24. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
25. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
[TBL] [Abstract][Full Text] [Related]
26. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
27. Prospective assessment of resection margin status following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma after standardisation of margin definitions.
Pine JK; Haugk B; Robinson SM; Darne A; Wilson C; Sen G; French JJ; White SA; Manas DM; Charnley RM
Pancreatology; 2020 Apr; 20(3):537-544. PubMed ID: 31996296
[TBL] [Abstract][Full Text] [Related]
28. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
29. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Impact of Time to Surgery in Patients With Resectable Pancreatic Ductal Adenocarcinoma.
Joliat GR; Labgaa I; Gilgien J; Demartines N
Pancreas; 2021 Jan; 50(1):104-110. PubMed ID: 33370031
[TBL] [Abstract][Full Text] [Related]
31. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study.
Li Z; Zhuo Q; Li B; Liu M; Chen C; Shi Y; Xu W; Liu W; Ji S; Yu X; Xu X
World J Surg Oncol; 2024 Jan; 22(1):1. PubMed ID: 38169384
[TBL] [Abstract][Full Text] [Related]
32. A case-matched comparison study of total pancreatectomy versus pancreaticoduodenectomy for patients with pancreatic ductal adenocarcinoma.
Xiong J; Wei A; Ke N; He D; Chian SK; Wei Y; Hu W; Liu X
Int J Surg; 2017 Dec; 48():134-141. PubMed ID: 29081373
[TBL] [Abstract][Full Text] [Related]
33. Severe postoperative complications decrease overall and disease free survival in pancreatic ductal adenocarcinoma after pancreaticoduodenectomy.
Lubrano J; Bachelier P; Paye F; Le Treut YP; Chiche L; Sa-Cunha A; Turrini O; Menahem B; Launoy G; Delpero JR
Eur J Surg Oncol; 2018 Jul; 44(7):1078-1082. PubMed ID: 29685757
[TBL] [Abstract][Full Text] [Related]
34. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.
Richter A; Niedergethmann M; Sturm JW; Lorenz D; Post S; Trede M
World J Surg; 2003 Mar; 27(3):324-9. PubMed ID: 12607060
[TBL] [Abstract][Full Text] [Related]
35. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
Matsumoto I; Tanaka M; Shirakawa S; Shinzeki M; Toyama H; Asari S; Goto T; Yamashita H; Ishida J; Ajiki T; Fukumoto T; Shimokawa M; Ku Y
Ann Surg Oncol; 2015 Jul; 22(7):2408-15. PubMed ID: 25487967
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.
Fukumoto T; Watanabe T; Hirai I; Kimura W
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):472-9. PubMed ID: 27246905
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression.
Kobayashi M; Mizuno S; Murata Y; Kishiwada M; Usui M; Sakurai H; Tabata M; Ii N; Yamakado K; Inoue H; Shiraishi T; Yamada T; Isaji S
Pancreas; 2014 Apr; 43(3):350-60. PubMed ID: 24622063
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study.
Delpero JR; Jeune F; Bachellier P; Regenet N; Le Treut YP; Paye F; Carrere N; Sauvanet A; Adham M; Autret A; Poizat F; Turrini O; Boher JM
Ann Surg; 2017 Nov; 266(5):787-796. PubMed ID: 28953554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
